Tenders Are Invited For Medicinal Products For The Blood And Blood-Forming Organs Human Coagulation Factor Viii Concentrate Containing Von Willebrand Factor For The Treatment Of Von Willebrand Disease In A Ratio Of At Least 2 Units Of Von Willebrand Factor To 1 Unit Of Coagulation Factor Viii.

Medicinal Products For The Blood And Blood-Forming Organs Human Coagulation Factor Viii Concentrate Containing Von Willebrand Factor For The Treatment Of Von Willebrand Disease In A Ratio Of At Least 2 Units Of Von Willebrand Factor To 1 Unit Of Coagulation Factor Viii.. 1. The Subject Of The Order Is The Supply Of Human Coagulation Factor Viii Concentrate Containing Von Willebrand Factor To Ensure The Continuity Of Treatment Of Patients With Von Willebrand Disease, In A Ratio Of At Least 2 Units Of Von Willebrand Factor To 1 Unit Of Coagulation Factor Viii - Hereinafter Coagulation Factor. 2. The Activity Of Von Willebrand Factor To The Activity Of Factor Viii In The Concentrate Should Be Not Less Than 2. This Means That In The Concentrate Intended For The Treatment Of Patients With Von Willebrands Disease, There Should Be At Least 2 (Two) Units Of Factor Viii Per 1 (One) Unit Of Factor Viii Von Willebrand Factor. Under The Concept Of Should Be Understood As Von Willebrand Factor For The Treatment Of Von Willebrand Disease, Contained In Human Coagulation Factor Viii Concentrate, In A Ratio Of At Least 2 Units Of Von Willebrand Factor To 1 Unit Of Coagulation Factor Viii. 3. Total Quantity (Purchase Quantity): 5,600,400 Iu. Von Willebrand Factor. 4. Dosage Proportions - In Accordance With Swz 5. The Clotting Factor Concentrate Must Be Delivered With A Set Enabling Its Administration. 6. When Selecting The Most Advantageous Offer, The Ordering Party Reserves The Right To Reduce The Purchase Of The Medicinal Product, But Not By More Than 20% Of Each Part Of The Above. The Subject Of The Order, If The Amount Allocated For The Execution Of The Order Is Exceeded Or If Objective And Justified Needs Arise, In Particular Changes In Patient Demand. 7. Pursuant To Art. 257 Of The Public Procurement Law. The Contracting Authority May Invalidate The Contract Award Procedure If The Public Funds That The Contracting Authority Intended To Use To Finance All Or Part Of The Contract Were Not Awarded To It. 8. Distribution List Of Direct Recipients For Whom The Purchase In Question Is Made Together With The Above-Mentioned Ordered The Number Of The Subject Of The Order Needed To Purchase, In Order To Ensure Uninterrupted Implementation Of The Health Policy Program Of The Minister Of Health Entitled The National Program For The Treatment Of Patients With Hemophilia And Related Hemorrhagic Disorders For 2024-2028 Will Be Provided To The Selected Contractor By The National Blood Center After Signing The Contract, In Accordance With The Reported Current Demand.

Refer document

FileName	File Description
Global Tender Document	Tender Notice